Overview
Imagene.Me is a company that offers genetic testing services, focusing on a wide range of genes associated with various health conditions, including cancer, reproductive issues, neurological disorders, and metabolic diseases. They provide insights into genetic predispositions that can influence individual health and well-being. The company analyzes thousands of genes to help individuals understand their genetic potential and health risks.
Financials
Revenue history (in k)
Filing timeliness
No financial statement for 2025 – the filing deadline has passed. 4 of 6 financial statements were filed late (the longest delay 89 days for 2021). All were audited by a statutory auditor.
- 2025not filed
- 202414/07/2025
- 202305/09/2024
- 202204/08/2023
- 202112/10/2022
- 202020/10/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2024.
Results vs industry
Industry
Authorized Representatives
Manner of representation
Two members of the management board acting jointly, or one member of the management board acting jointly with a commercial proxy, always including the member of the management board responsible for financial matters if such a member has been appointed.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Was a VAT taxpayer from 2018-08-09 to 2026-04-22.
Reason for removal: Art. 96 ust. 9a pkt 2 (VAT returns not filed for 3 consecutive months or a quarter)
Debt
2 active proceedings recorded in KRZ.
| Registration date | Proceeding type | Status | |
|---|---|---|---|
| Jun 22, 2026 | Proceedings after filing an arrangement approval application | In progress | |
| Feb 19, 2026 | Arrangement approval proceedings | In progress |
MSiG notices
| Publication date | Event | |
|---|---|---|
| Sep 10, 2025 | Shareholders' meeting convened |
Public aid
17 public aid cases recorded, with a total value of $844,301.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Oct 10, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $0$0 | Prezes Zakładu Ubezpieczeń Społecznych | |
| Nov 11, 2024 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $3,300$3,300 | Marszałek Województwa Podlaskiego | |
| Feb 22, 2024 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $1,103$1,103 | Prezes Zakładu Ubezpieczeń Społecznych |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2022-02-01 | Development of a system for semi-automated specialist teleconsultations in endocrinology, cardiology, allergology, gastroenterology and oncology | $384.1K$384,132 | Regional Operational Programme for Województwo Podlaskie for 2014-2020 | |
| 2020-04-01 | Research and development work by Imagene.me S.A. to develop a new product in the field of personalised medicine | $535.1K$535,090 | Regional Operational Programme for Województwo Podlaskie for 2014-2020 |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Data4cure Polandsp. z o.o. | $1,824,382.17 | data4cure.com | ||
| Epolmedsp. z o.o. | $1,412,729.66 | epolmed.pl | ||
| Upside Labsp. z o.o. | $1,468,774.96 | upsidelab.io | ||
| Hearmesp. z o.o. | $1,410,971.68 | hearme.pl | ||
| Idea3sp. z o.o. | $1,044,249.82 | idea3.pl | ||
| Powermedsp. z o.o. | $768,470.48 | powermed.com.pl | ||
| Animativsp. z o.o. | $701,101.44 | animativ.pl | ||
| Diagnova Technologiessp. z o.o. | $445,925.86 | diagnova.pl | ||
| BrainscanS.A. | $411,063.49 | brainscan.ai | ||
| Komessp. z o.o. | $376,497.49 | komes.com.pl |
Change history
| Date | Event | |
|---|---|---|
| 2025-03-07 | Share capital increase (3,619,340.00 PLN → 4,102,432.00 PLN) | |
| 2025-03-03 | Share capital increase (2,492,340.00 PLN → 3,619,340.00 PLN) | |
| 2024-06-12 | Share capital increase (492,340.00 PLN → 2,492,340.00 PLN) | |
| 2023-10-12 | Share capital increase (365,178.00 PLN → 492,340.00 PLN) | |
| 2023-05-11 | Share capital increase (323,901.00 PLN → 365,178.00 PLN) |
FAQ
Last updated: 2026-03-29